Thrombocytopenia in critically ill patients

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 5, 2008, Pages 417-424

  Levi, Marcel ^a   Löwenberg, Ester C ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Coagulation; Immune thrombocytopenia; Intensive care; Platelets; Sepsis; Thrombotic microangiopathy

Indexed keywords

ARGATROBAN; HEPARIN; IMMUNOGLOBULIN; LEPIRUDIN; PROTEIN; STEROID; WARFARIN;

ADVERSE OUTCOME; BLEEDING; BLOOD VESSEL WALL; CRITICALLY ILL PATIENT; DIFFERENTIAL DIAGNOSIS; HEALTH; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; NONHUMAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW; RISK; RISK ASSESSMENT; SEPSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE COUNT;

BLOOD PLATELETS; CELL ADHESION MOLECULES; CRITICAL ILLNESS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INTEGRINS; MEMBRANE PROTEINS; PLATELET COUNT; SELECTINS; THROMBOCYTOPENIA;

EID: 55049123108     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1092871     Document Type: Review

References (57)

1. Levi M. Platelets. Crit Care Med 2005;33:S523-S525
2. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care 2006;10:222-228
3. Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000;28:1871-1876
4. Baughman RP, Lower EE, Flessa HC, Tollerud DJ. Thrombocytopenia in the intensive care unit. Chest 1993;104:1243-1247
5. Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002;30:1765-1771
6. Stephan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU. Chest 1999;115:1363-1370
7. Hanes SD, Quarles DA, Boucher BA. Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother 1997;31:285-289
8. Akca S, Haji Michael P, de Medonca A, Suter PM, Levi M, Vincent JL. The time course of platelet counts in critically ill patients. Crit Care Med 2002;30:753-756
9. Oppenheim-Eden A, Glantz L, Eidelman LA, Sprung CL. Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med 1999;25:63-67
10. Hawiger JJ. Adhesive interactions of blood cells and the vascular wall in hemostasis and thrombosis. In: Colman RW, Hirsh J, Marder V, Salzman E, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 3rd ed. Philadelphia, PA: J.B.Lippincott; 1994:639-653
11. Ware JA, Heistad DD. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions. N Engl J Med 1993;328:628-635
12. Woodside DG, Liu S, Ginsberg MH. Integrin activation. Thromb Haemost 2001;86:316-323
13. Ruoslahti E. Integrins. J Clin Invest 1991;87:1-5
14. Phillips DR, Prasad KS, Manganello J, Bao M, Nannizzi-Alaimo L. Integrin tyrosine phosphorylation in platelet signaling. Curr Opin Cell Biol 2001;13:546-554
15. Clemens R, Pramoolsinsap C, Lorenz R, Pukrittayakamee S, Bock HL, White NJ. Activation of the coagulation cascade in severe falciparum malaria through the intrinsic pathway. Br J Haematol 1994;87:100-105
16. Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 2001;86:214-221
17. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002;300:729-735
18. Romo GM, Dong JF, Schade AJ, et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 1999;190:803-814
19. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000;192:193-204
20. Clemetson JM, Polgar J, Magnenat E, Wells TN, Clemetson KJ. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem 1999;274:29019-29024
21. Jung SM, Takemura Y, Imamura Y, et al. Collagen-type specificity of glycoprotein VI as a determinant of platelet adhesion. Platelets 2008;19(1):32-42
22. Silverstein RL, Asch AS, Nachman RL. Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest 1989;84:546-552
23. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-1234
24. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003;1:1335-1342
25. Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002;99:3971-3977
26. Jung SM, Moroi M. Activation of the platelet collagen receptor integrin alpha(2)beta(1): its mechanism and participation in the physiological functions of platelets. Trends Cardiovasc Med 2000;10:285-292
27. Massberg S, Konrad I, Bultmann A, et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004;18:397-399
28. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 2001;86:189-197
29. Jurk K, Clemetson KJ, De Groot PG, et al. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J 2003;17:1490-1492
30. Roberts DD, Sherwood JA, Spitalnik SL, et al. Thrombospondin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence. Nature 1985;318:64-66
31. Brittain JE, Mlinar KJ, Anderson CS, Orringer EP, Parise LV. Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. J Clin Invest 2001;107:1555-1562
32. Ill CR, Engvall E, Ruoslahti E. Adhesion of platelets to laminin in the absence of activation. J Cell Biol 1984;99:2140-2145
33. Thiagarajan P, Kelly KL. Exposure of binding sites for vitronectin on platelets following stimulation. J Biol Chem 1988;263:3035-3038
34. Mavrommatis AC, Theodoridis T, Orfanidou A, Roussos C, Christopoulou-Kokkinou V, Zakynthinos S. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 2000;28:451-457
35. Levi M. Platelets in sepsis. Hematology 2005;10(Suppl 1):129-131
36. Folman CC, Linthorst GE, van Mourik J, et al. Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis? Thromb Haemost 2000;83:923-930
37. Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 1997;103:114-120
38. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007;35:2191-2195
39. Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 2003:497-519
40. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-592
41. Levi M, van Der PT, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006;32:33-39
42. Gando S. Tissue factor in trauma and organ dysfunction. Semin Thromb Hemost 2006;32:48-53
43. Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006;32:11-23
44. Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost 2006;32:5-10
45. Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-1330
46. Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the international society of thrombosis and maemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004;32:2416-2421
47. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004;2:1924-1933
48. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600
49. Tsai HM. Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 2003;23:388-396
50. van den Born BJ, van der Hoeven NV, Groot E, et al. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension 2008;51:862-866
51. Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003;23:745-753
52. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl JMed 1995;332:1330-1335
53. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-555
54. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30
55. Makoni SN. Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature. Heart 2001;86:E18
56. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007;356:2301-2311
57. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004;164:361-369